Analytical Data
-
Gene name
CDA2
- Application
-
Alternative Names
CDA2; YLR308W; L2142.1Chitin deacetylase 2; EC 3.5.1.41
-
Species
Saccharomyces cerevisiae
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q06703
-
Expression Region
26-312aa
-
Molecular Weight
34.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDA2 recombinant protein research is rooted in the growing interest in enzyme therapy and its potential applications in biotechnology and medicine. CDA2, or cytidine deaminase type 2, is an enzyme that plays a crucial role in nucleotide metabolism by catalyzing the deamination of cytidine and deoxycytidine to uridine and deoxyuridine, respectively. This enzymatic activity is significant in various biological processes, including antiviral responses and the regulation of cellular metabolism. Given the importance of nucleotide metabolism in a range of diseases, including cancer and viral infections, understanding CDA2's structure and function through recombinant protein studies can provide insights into its therapeutic potential. Researchers have focused on producing CDA2 in recombinant systems to study its biophysical properties, enzymatic mechanisms, and potential applications in drug development. By utilizing techniques like gene cloning, expression in bacterial systems, and subsequent purification, scientists aim to generate sufficient quantities of the enzyme for further investigations. Additionally, the study of CDA2's interactions with substrates and inhibitors may reveal novel therapeutic strategies for diseases where nucleotide metabolic pathways are dysregulated. Overall, CDA2 recombinant protein research holds promise for advancing our understanding of enzymatic functions and their applications in medicine and biotechnology.
